Method of neoadjuvant chemotherapy of mammary gland cancer |
|
|
IPC classes for russian patent Method of neoadjuvant chemotherapy of mammary gland cancer (RU 2338545):
Combined therapy for treatment of acute leukemia and myelodisplastic syndrome / 2338535
Invention can be used for treatment of an acute myelogenetic leukemia or myelodysplastic syndrome. For this purpose use a combination of preparations hemetuzumab ozohamicin, daunorubicin and cytarabinum in certain doses and regimens.
 Staufosporine derivatives as inhibitors of receptor tyrosine kinase flt3 activity / 2337692
Invention concerns application of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9N-diindolo [1,2,3-gh:3', 2', 1'-lm] pyrrolo[3,4-j][1,7]benzodiasonine-11-yl]-N-methylbenzamide of formula
 Antitumoral agent on basis of immunopolisome biological structure, way of its obtaining and vectorial delivery in central nervous system at tumoral process / 2336901
Invention concerns biopharmacology and medicine area. The antitumor agent representing a immunoliposome biological structure, including a liposome containing the therapeutic agent, sewed with a vector of peptide nature, thus for treatment of CNS tumors is declared, the liposome contains the therapeutic agent in a water phase, as a vector contains monoclonal antibodies to CD34+, and a linking represents 2-iminotiolan (IT) in 0.1% concentration. As a therapeutic agent, immunoliposome contains the substance chosen from the group: Daunomycin, Carminomycinum, Melphtalan, Methotrexatum, Cytarabinum, Doxorubicinum, Ricine. The method of obtaining of an antitumoral agent and way of inhibition of a tumor of the brain, consisting in agent administering due to item 1 in a pharmaceutically suitable carrier in effective quantity is declared also. Thus preliminary administer parenterally a preparation of hematological stem cells CD34+.
Method of obtaining shelf fungus ethanolic extract / 2336888
Invention concerns the pharmaceutical, food and cosmetic industry. Perform extraction of the raw material crushed with water with obtaining of a water extract and pulp. The pulp, obtained after extraction of raw materials by the water, is extracted in two steps with ethyl alcohol. At the first step of extraction the constrictor is extracted within 4-6 hours using the following proportion: ethyl alcohol 1:(5-7) with concentration of alcohol of 30% either 50%, or 70%, at temperature of 60-75°C, obtaining an ethanolic extract of the first step of extraction and pulp; then, this pulp is repeatedly extracted within 4-6 hours with ethyl alcohol using the following proportion: ethyl alcohol 1:(3-5) with concentration of alcohol of 30% either 50%, or 70%, at temperature of 60-75°C, obtaining an ethanolic extract of the second step of extraction and pulp. After that the ethanolic extract of the first step of extraction is aggregated with the ethanolic extract of the second step of extraction.
 Pyrimidine derivatives, characterised by antiproliferative activity, and pharmaceutical composition / 2336275
Invention relates to new pyrimidine derivatives of formula I and their pharmaceutically acceptable salts, which are selective inhibitors of kinases KDR, FGFR and PDGFR and can be used for treatment of oncological diseases. Compound of formula I corresponds to structural formula
Method of rectal cancer treatment / 2336038
Within preoperative period patients are drew with blood sample in amount 200 ml. Using centrifugation process plasma is separated from blood. Autoplasma in amount 40 ml is placed to the first bottle added with 5-fluorouracil 500 mg. The second bottle contains remained blood corpuscles, plasma and 5-fluorouracil 1000 mg. Bottles are incubated separately within 40 minutes at 37°C. Then rectum is excised. During operation incubated blood of the second bottle with chemical added is introduced intravenously drop-by-drop. After tumour rectum is extracted, haemostatic sponge impregnated with incubated autoplasma of the first bottle with chemical added is placed in tumour box (on sacral bone). Then perineal wound is tampon or cut down.
 Coordination complex of platinum (ii) diaminocyclohexane with block copolymer containing polycarboxylic acid segment and including anticancer agent / 2335512
Invention concerns coordination complex of platinum (II) diaminocyclohexane with block copolymer containing structure of the general formula PEG-block-poly(carbo), where PEG is a poly(ethyleneglycol) segment, and carbo is a repeating chain containing carboxylic group in the side chain, and platinum (II) diaminocyclohexane is immobilised by block copolymer due to linkage between carboxylic carbo residue anion and platinum; as well as method of obtaining the complex and anticancer composition including effective anticancer quantity of coordination complex and pharmaceutically acceptable carrier. In addition, invention concerns coordination complex of platinum (II) diaminocyclohexane and block copolymer with structure of the general formula (1-a)
Peptide analogues gh-rh with opposing action, way of depression of gh level, way of depression of igf-inigf-ii level, application for inhibition of growth of cancer cells, pharmacologically acceptable composition (variants) / 2335506
New types of synthetic opposing analogues hGH-RH(1-29)NH2 are offered. The given analogues inhibit interaction of endogenous hGH-RH with hypophyseal GH-RH receptors and thus interfere with release of a growth hormone. The analogues also suppress a proliferation in cancer tissues of the person by immediate influence on cancer cells. Increased inhibitory efficiency of the new analogues, in comparison with earlier described, is a consequence of replacement of different amino acids.
 Polymorphs of pyrrol-substituted 2-indolinone proteinkinase inhibitors / 2335502
Invention concerns polymorphs of 1-pyrrol-substituted 2-indolinone compound (2-pyrrolidine-1-ylethyl)amide 5-(5-fluor-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-carboxylic acid, namely polymorphic form of the formula I:
 Arylcarbonylpiperazines and heteroarylcarbonylpiperazines for tumour treatment (versions), medication (versions), method of obtaining and method of tumour treatment / 2335496
Invention concerns aryl- or heteroarylcarbonylpiperazine compound of the general formula (I)
 Method of plasma or blood serum storage for obtaining of immunoglobulene and albuminous biological preparations / 2338375
In this method process native plasma or blood serum chemical reagents. Consistently bring in Phenolum to its final concentration (0.7±0.2)%, condition within 5 days at temperature (10±2)°C and then add ammonia sulphate to concentration of 50 % from saturation. Store the obtained protein suspension at temperature (10±2)°C and selectively transfer in immunoglobulin and albuminous half-finished products by centrifugation of sulphatic suspensions, for the purpose of separate obtaining of immunoglobulin deposits and albumins, extract the deposits in 1-2% solution of calcium chloride, remove slightly solublecalcium sulfate using centrifugation and reprecipitate target proteins from the supernatant solution with polyethyleneglycol-6000.
Method of normovolemic autoplasma haemodilution in elective surgery associated with mass haemorrhage / 2337718
Prior to surgery within 12 months to 3 days autoplasma is prepared through 2-3 sessions of double plasmapheresis at minimum interval of sessions 3 days and then frozen. Then 1 hour before operation blood exfused till haematocrit is decreased to 25% and supplied with defrozen auoplasma. After surgery is started haemorrhage is compensated with crystalloid solutions and autoplasma in ratio 1:1. After final surgical haemostasis is complete exfused blood is transfused.
Method of bleeding prevention associated with tonsillectomy / 2336040
Before operation autoblood is sampled followed by thrombocyte-rich plasma clot preparation. Clot is squeezed to thickness 2-3 mm and inlaid to open wound formed after tonsil extraction.
Method of rectal cancer treatment / 2336038
Within preoperative period patients are drew with blood sample in amount 200 ml. Using centrifugation process plasma is separated from blood. Autoplasma in amount 40 ml is placed to the first bottle added with 5-fluorouracil 500 mg. The second bottle contains remained blood corpuscles, plasma and 5-fluorouracil 1000 mg. Bottles are incubated separately within 40 minutes at 37°C. Then rectum is excised. During operation incubated blood of the second bottle with chemical added is introduced intravenously drop-by-drop. After tumour rectum is extracted, haemostatic sponge impregnated with incubated autoplasma of the first bottle with chemical added is placed in tumour box (on sacral bone). Then perineal wound is tampon or cut down.
Method of elimination of orbit posttraumatic defects / 2330636
Radial vein blood is sampled before operation. Plasma rich in thrombocytes is isolated from blood sample. During operation bone autografts taken from parietal region are placed in defect or defects area within orbit. It is accompanied with simultaneous additional bone autograft taking of size no more than 20×15 mm. It is used to produce bone chips mixed with prepared plasma rich in thrombocytes. Produced mixture is added with 10% CaCl solution in ratio 10:1 and stirred to plasticity condition. Produced mixture is place in sheets between inserted bone blocks and in retrobulbar orbit area. Then eyeball is delivered forward and hypercorrected considering intraoperative hypostasis of soft tissues. For this purpose central pupillary line is moved to correct position, with regular distribution of bone chips within retrobulbar areas.
Method of hematogen production / 2329817
Invention refers to medicine, in particular to haematology, and concerns new preparations production of animal blood. Method includes use of all components of animal clotted blood, added with sacchariferous substances in ratio 1:1 and following mixture sterilisation at temperature 60-65°C within 24 hours, thus used mixture consists of erythrocyte mass and liquid blood, produced as a result of blood clot isolation in ratio 1:1. Invention provides production of hematogen with lower haemoglobin content and higher blood serum protein content.
Method of children acute purulent maxillary sinusitis or maxillary ethmoiditis treatment / 2329814
Invention refers to medicine, specifically to otolaryngology, and can be used for treatment of children acute purulent maxillary sinusitis or maxillary ethmoiditis. For this purpose, maxillary sinus preliminary washed with distilled water is introduced with medicinal product Actoinvite. Thus Actoinvite is diluted with distilled water 1:10, and 1 ml of solution is introduced through Kulikovsky's needle once in two days. Invention provides increased efficiency of disease treatment, prevents conversion of acute process to chronic due to stimulated neutrophil phagocytic activity, accelerated processes of inflammation resolution.
Anaesthesia method applied for adrenalectomy caused by epinephros pheochromocytoma / 2329799
Invention refers to medicine specifically to anaesthesiology and blood-saving techniques in anaesthesiology and resuscitation science, and can be used as anaesthetic management within adrenalectomy caused by epinephros pheochromocytoma. For this purpose operation is preceded with complex patient examination. Preanesthetic medication applied one day before and in the morning prior to operation implies introduction of tableted phenozepam dosed 0.0005-0.001 g, and 30 min before operation sybazone is injected intramuscularly in dosage 10 mg combined with Dimedrol in dose 10 mg. In operating theatre monitoring, puncture and catheterisation of central vein are performed. Then epidural cavity is punctured at height Th7-L1, catheterised so that catheter cap is being placed at height Th5-Th11 to provide following postoperative anaesthesia. Unassisted breathing is accompanied with oxygen inhalation through anaesthesia apparatus mask at rate 5-8 l/minute. Preanaesthetic medication is completed with intravenous bolus dosing of 0.1% atropine solution dosed 0.005-0.007 mg/kg. 5-10 minutes prior to surgical intervention patient blood is exfused in volume 1.0 litres in case arterial pressure is reduced lower than 140/90 mm m.c., and in volume 1.5 litres in case arterial pressure is reduced higher than 140/90 mm m.c. followed by drop-by-drop intravenous introduction of warmed to 37-42°C crystalloid solution either acesol, or trisol, or lactasol or Ringer's solution. Afterwards anaesthesia is added with intravenous bolus dosing to central vein of 2% thiopental sodium solution in dosage 4-5 mg/kg, 0.005% fentanyl solution dosed 0.0025-0.0035 mg/kg followed by intubation of trachea accompanied with precurarisation by introduction of either pipecuronium bromide (arduan) in dosage 1-2 mg or rocuronium bromide (esmerone) in dosage 10-20 mg and against muscular relaxation introduction of 2% suxamethonium iodide solution (dithylinum) in dosage 1.5-2 mg/kg, then patient is transferred to artificial pulmonary ventilation. Within epinephros central vein clipping and crossing for separation of pathologically modified epinephros complete or partial autoblood is reinfused until patient arterial pressure is completely stabilised at level 100-110/60-70 with following infusion crystalloids warmed up to 37-42°C. In case of partial autoblood reinfusion, repeated reinfusion of the rest autoblood volume is performed within the first days of early postoperative period. Anaesthesia management within all stages of surgical intervention is carried under artificial pulmonary ventilation by inhalation of mixed nitrogen monoxide and oxygen at ratio 2:1 to 3:1 using reversive breathing circuit of ventilation respiratory capacity 7-8 ml/kg at minute ventilation 100-120 ml/kg, intravenous introduction of fentanyl dosed 5-6 mkg/kg/h, as well as introduction of arduan in dosage 2-4 mg every 40-60 minutes of operation procedure or introduction of esmerone in dosage 10-20 mg every 25-35 minutes of operation procedure. Anaesthesia is completed at stage of operation termination by termination of intravenous introduction of fentanyl and relaxing agents against continuation of artificial pulmonary ventilation by oxygen-air mix with FiO2 equal to 0.4-0.6. Method provides stabilisation of haemodynamics and cardiac activity during adrenalectomy without vasopressor application.
 Method of inferior limb trophic ulcers treatment associated with postthrombotic disease / 2328288
Invention can be used for treatment of inferior limb trophic ulcers caused by postthrombotic disease. For this purpose vein blood is sampled in amount 400-500 ml with following centrifugation during 15 mines at rate 2000 rotations per minute. Produced erythromass is dissolved with 200 ml of 0.9% physiologic saline and intravenously introduced to patient. Patient plasma in amount 200 ml is placed in thermostat and incubated within 20 mines at temperature 37C°. Then incubated plasma is added with 20 mg of agent Vasaprostan and produced received mix is slowly intravenously introduced to patient drop-by-drop within 2-3 hours once a day throughout 10 days.
Method of human blood coagulation viii factor concentrate production and related product / 2326689
Invention refers to method of human blood coagulation VIII factor production and related product. Method includes blood serum as cryoprecipitate, heparine added, PEG-4000, centrifugation, supernatant is added with tributyl phosphate and Twin-80, repeated centrifugation, sediment washed with sodium chloride, then it is dissolved in tris-HCl buffer with additives, let through column filled with gel and attached antibodies to Willebrand's factor, factor VIII elution, dialysis. Produced concentrate does not contain Willebrand's factor and has activity not less than 300 ME/mg of protein with purity not less 98% and contains albumin of concentration of 0.1%. Product is lyophilized with further processing.
 Method for interhospital transportation of patients with multitrauma / 2337659
Before the patient is placed into anti-shock suite (ASS) "Kashtan", the crystalloids solution infusion in dose 5-7 ml/kg of body weight is performed during 10-15 min. Then the patient is placed into ASS "Kashtan", and pneumocompression is applied over injured body parts up to 40 mm Hg, and over the rest parts 15-20 mm Hg. In first 30 min. of transportation the crystalloids solution is infused in dose 10-15 ml/kg of body weight. In addition, voluven is administered in doses as follows: in shock degree I - 10 to 15 ml/kg of body weight, in shock degree II - 20 to 25 ml/kg of body weight, in shock degree III - 30 to 35 ml/kg of body weight. The method provides sparing transportation of patients, including long-time transportation, owing to fast normalisation of central hemodynamics indices by the developed regimen of compression application in ASS, simultaneously with hypovolemia correction subject to shock degree.
|
FIELD: medicine; oncology. SUBSTANCE: from the first day of treatment centrifugate the autoblood obtained by vascular access in volume of 2400-2600 ml, 1600 ml of supernatant plasmas select in sterile vials, expose to filtrational detoxicating with use of filter F60S with rate of perfusion of 250-300 ml/minute. Then the obtained albuminous concentrate of autoplasma in volume 700-800 ml place in sterile vials in the equal portions corresponding to number of planned introductions of cytostatics under the scheme. Vials contain in a refrigeration cabinet at t-20°C. At carrying out of polychemotherapy by cytostatics under the scheme, an albuminous concentrate defreeze at t +4°C, each antitumoral preparation plant in 10 ml of a normal saline solution, enter into a vial with an albuminous concentrate, incubate at t +37.0°C within not less than 30 minutes and reinfuse them intravenously driply, spend 1-2 courses of neoadjunt treatment. EFFECT: increase of efficiency of treatment at the expense of transfer of patients in an operable condition; reduction of the sizes of a tumour and lymphonoduses and depression of toxicity of spent polychemotherapy. 1 ex
The invention relates to medicine, namely to Oncology, and can be used in the treatment of patients with locally advanced breast cancer with metastases to the supraclavicular lymph nodes on the affected side. Known "Method neoadjuvant drug therapy for locally advanced cancer of the breast" (see Merlinia, Ehidirova, Lggwav, Vdemidova, Meelhuysen. "Russian cancer journal cancer research them. Boy (dir. - academician. RNA) RAMS, M., 5.2001, p.32, 33 "Contemporary opportunities and challenges neoadjuvant drug therapy for locally advanced cancer of the breast"). The method consists in the following: 51 patients with locally advanced breast cancer (II-IA stage 15, IIIB - 36) received neoadjuvant chemotherapy in the following modes: 1st - epirubicin 50 mg/m2and cisplatin 60 mg/m2intravenous 1 every 3 weeks, Ftorafur 400 mg 3 times a day orally daily, long-term; 2nd - novatron 10 mg/m2and cisplatin 60 mg/m2intravenous 1 every 3 weeks, Ftorafur 400 mg 3 times a day orally daily, long-term; 3rd - navelbine 20 mg/m2intravenous in the 1st and 8th days, Novantrone 10 mg/m2intravenously at day 1. The intervals between courses of 3 weeks, the number of courses 3-6. Ablative surgery performed in different modes in 1865% of patients, that largely depended on the extent of tumor spread in patients enrolled in the study. Complete and partial clinical regression of the tumor did not influence long-term results of treatment. Made in the neoadjuvant chemotherapy effect was meaningful only to reduce the amount of subsequent operations. There is a possibility to reduce the amount of subsequent operations. However, you should expect rapid progress in the coming years. There is a method of treatment of patients with multiple myeloma (see Acholonu, Vigabatrin. Multiple myeloma, Saint-Petersburg, 1995 pagination 126), including polychemotherapy according to the scheme of the CSR(K)P, CSVK, CSIT, in which 7 to 10 days of treatment plasmapheresis. The feasibility of combining chemotherapy and plasmapheresis due to the reduction of the time of receipt of the effect of treatment, and the effect on immunocompetent cells. However, this method has drawbacks: it does not provide reinfusion autoplasma, which does not allow to fill proteins at the expense of own and use their modifying effect on chemotherapy during incubation. Unlike patients with myeloma disease, accompanied by hyperproteinemia, this approach in cancer patients with solid tumors not pathogenetically justified. This immunocorrective properties plasmate is for use only at the end of treatment, however, the immunological mechanisms, starting with the first day of treatment, it is important to achieve high efficiency. In addition, daily use hardware plasmapheresis further enhances the invasiveness of the treatment. There is a method of breast cancer treatment (see patent No. 2203687 published. Bull. No. 13 from 10.05.03.), chosen as a prototype, including intravenous drip of anticancer chemotherapy, pre-incubated with autoplasma, characterized in that, starting from the first day of treatment, 1 week produce continuous plasmapheresis, take autoplasma in the number of 600-800 ml, divide it into 6 equal parts, 3 of which are used for incubation at 137°C for 40 min with chemotherapy: vincristine 1 mg, methotrexate 30 mg, fluorouracil 750 mg, cyclophosphamide 800 mg in 1, 8 days of treatment, doxorubicin 30 mg 1, 3, 5, 8, 10, 12 days of treatment with subsequent intravenous drip reinfuse and the other 3 injected intravenously for detoxification, alternating infusion of chemotherapeutic agents and detoxification through the day. There is a method of breast cancer treatment is applied during the entire course of treatment with the use of autoplasma for drug administration, has a positive clinical effect. However, the presence in the plasma component of blood of ballast substances which, toxic substances, metabolites of exogenous and endogenous origin, which also interact with albumin, determines the reduction of binding activity of albumin to chemotherapy. The aim of the invention is to improve the quality of detoxification, treatment autoplasma, improving treatment effectiveness - improving tumorotropic chemotherapy while minimizing its toxic effect. This goal is achieved by the fact that from the first day of treatment received vascular access autochrome in the amount of 2400-2600 ml centrifuged, the supernatant plasma is taken in sterile vials, volume plasmaexact is 1600 ml, the resulting autoplaza subjected to filtration detoxification apparatus ADM "Frezenius" using filter F60S with a perfusion rate of 250-300 ml/min, get protein concentrate autoplasma volume 700-800 ml, placed in sterile vials portions of equal volume and corresponding to the number of planned introductions drugs under the scheme, the bottles are kept in the refrigerator at t -20°C, when conducting polychemotherapy protein concentrate autoplasma defrost at t +4°With each anticancer drug diluted in 10 ml saline solution, is injected into the vial containing protein concentrate, incubated at t +37,0°C for at least 30 minutes and is re-infused them inside the venous drip, teach 1-2 courses of neoadjuvant treatment. The way neoadjuvant chemotherapy for breast cancer is new, because it is unknown the level of medicine in the field of chemotherapy in patients with breast cancer as neoadjuvant component. The novelty of the invention lies in the fact that for the first time in the treatment of patients with locally advanced breast cancer the method of neoadjuvant chemotherapy on protein concentrate autoplasma. When using autoplasma for chemotherapy, the main active principle is albumin, interacts with the overwhelming amount of drugs in the absence of the effect of competitive binding with uniform elements of blood, due to its physiological functions in the body and convincingly proven in experimental studies (Sidorenko US, 1996, 2000; Vladimirova LU, 2000, 2001, 2005). However, the presence in the plasma component of blood of ballast substances, toxic substances, metabolites of exogenous and endogenous origin, which also interact with albumin, determines the reduction of binding activity of albumin to chemotherapy. An important aspect is to develop a new high-tech method of processing, filtering autoplasma through hemofilter, POS is alaysia not only make detoxification, but to get the highest effective concentration of autoantibody in a unit volume of plasma. Complex treatment of patients with locally advanced common breast cancer with neoadjuvant chemotherapy on protein concentrate autoplasma as a natural carrier of pharmacological preparations provides "address" transport and delivery to the organs-targets. It enhances the effectiveness of chemotherapy while minimizing its toxic effects on the body and enabling the adaptive mechanisms of regulation of homeostatic systems. The invention "Method of neoadjuvant chemotherapy for breast cancer" is industrially applicable, as may be used in health care, hospitals with cancer, oncologic dispensaries, cancer research institutes. The method of neoadjuvant chemotherapy on protein concentrate autoplasma in the treatment of patients with locally advanced breast cancer performed as follows. To obtain a protein concentrate autoplasma the patient discretely produce fence autologous blood in the number of 2400-2600 ml portions at 300-500 ml using containers "Remocon" the appropriate volume. Vascular access for collection of autologous blood - catheterization accessories the historic Vienna. Received blood discrete gravitational plasmapheresis apparatus RS-6M. Modes of separation of blood: the velocity (V) 2200 rpm, time (t) 17 minutes the Supernatant plasma is taken into sterile vials and the cell sediment reinfusion plasmaexact is 1600 ml. In order to replace the volume plasmaexact injected plasma-substituting (reopoliglyukin, reportan etc) and crystalloid solutions (5%, 10% glucose, 0.9% sodium chloride solution and so on). The resulting autoplasma subjected to filtration detoxification apparatus ADM "Frezenius" using filter F60S with a perfusion rate of 250-300 ml/min Obtained protein concentrate autoplasma volume 700-800 ml collected in a sterile vials portions of equal volume. The number of portions corresponds to the number of planned during the course of chemotherapy injections of drugs. Protein concentrate autoplasma stored in a refrigerator at t -20°C. Before the introduction of the concentrate autoplasma thawed at t +4°C. Each anticancer drug diluted in 10 ml saline solution, is injected into the vial containing protein concentrate, incubated at t +37,0°C for at least 30 minutes and is re-infused intravenous drip. Neoadjuvant polychemotherapy is held by CMFA scheme: Methotrexate 25 mg 1.8 days; 5-fluorouracil 500 mg in 1, 3, 5, 8, 10, 12 days; Cyclophosphamide 200 mg in 1, 3, 5, 8, 10, 12 days;Doxorubicin 20 mg in 1, 3, 5, 8, 10, 12 days. Patient A., age 38, IB. No. 3276/x appealed to RNII in March 2006 for cancer of the right breast with metastasis to axillary lymph nodes on the right, T4N2M0, st.IIIB, gr.IIa. When needle biopsies No. 4059-60 from 3.03.06,: usernotification carcinoma. Hospitalized for examination and treatment in the Department of chorionic gonadotropin. When viewed in the upper outer quadrant of the right breast sedentary tumor to 4.0-4.5 cm in diameter, with indistinct contours, infiltration of the skin, the strands to the areola and nipple. In the right axillary region of the lymph node to 2.5 cm in diameter, partially offset. On the mammogram of the right breast from 3.03.06,: vermelerinin quadrant of the right breast dense shadow education irregular stellate form, 2,5×to 2.5×2.0 cm with multidirectional, connective tissue, radiant strands. Subaxillary-metastatic lymph node, 3,0*3.5 cm with clear contours. The local status of the patient was consistent with inoperable tumor process, it was not possible to conduct a radical treatment in adequate amounts. Received 2 courses of neoadjuvant polychemotherapy (PCT) on protein concentrate autoplasma. 1 course. 7.03.06, To obtain a protein concentrate autoplasma the patient suck the East access via peripheral (elbow) Vienna produced discretely fence autoblood portions of 500 ml in the amount of 2400 ml using plastic containers Remocon" the appropriate volume. Spent discrete gravitational plasmapheresis apparatus RS-6M. Modes of separation of blood were: speed (V) 2200 rpm, time (t) 17 minutes the Supernatant plasma was collected in sterile vials and the cell sediment was repusively. The amount of plasmaexact amounted to 1600 ml. In order to replace the volume plasmaexact introduced plasma-substituting (reopoliglyukin, reportan) and crystalloid solutions (5%, 10% glucose, 0.9% sodium chloride solution). The resulting autoplaza was subjected to filtration detoxification apparatus ADM "Frezenius" using filter F60S with a perfusion rate of 250-300 ml/min Obtained protein concentrate autoplasma volume of 720 ml were collected in sterile vials portions of equal volume. Their number corresponds to the number of planned during the course of chemotherapy injections of cytostatics - 6 servings. Protein concentrate autoplasma kept in the refrigerator at t -20°C. Before the introduction of the concentrate autoplasma were thawed at t +4°C. Each anticancer drug was dissolved in 10 ml of saline, was injected into the vial with the protein concentrate, incubated at t +37,0°C for at least 30 minutes and was repusively intravenous drip. 9-21.03.06 g - 1 course of neoadjuvant chemotherapy on protein concentrate autoplasma in CMFA scheme. Total introduced intravenously at 50 mg methotrexate is, 3000 mg of 5-fluorouracil, 1200 mg of cyclophosphamide, 130 mg of epirubicin. Suffered no complications. The treatment results in decreased tumor to 3.5-4.0 cm in diameter, its outlines became clearer, increased smexiest disappeared infiltration of the skin, strands to the areola and nipple became less pronounced. The lymph node in the right axillary region decreased to 1.5 in diameter, was moving. 2 course 13 25.04.06, similar to the 1st course. Suffered with mild dyspeptic symptoms. As a result of treatment the tumor was 2.5 cm in diameter with clear contours, mobile, infiltration of the skin no, weakly expressed tictacti to the nipple. In the right axillary region of the lymph node 1.5 cm in diameter, with a distinct separation furrow. On the mammogram after treatment 11.05.06, the tumor in vermelerinin quadrant of the right breast has decreased to 2.0*1.5 x 1.0 cm, the structure became less dense compared to the original local status, the fibres are less pronounced. Right axillary lymph node was fragmentirovana on 2 things: 1.0 and 0.5 cm in diameter. As a result of treatment according to who criteria noted partial regression of the tumor (76,0%) and metastatic lymph node (95.2 percent). The patient was transferred in operable condition. The patient 12.05.06, performed surgery radical mastectomy on the right, pT4N1M0, st.IIIB. Microreport: m is Nochnoi gland after treatment expressed medicinal pathomorphosis, sclerosis, a tumor not detected in axillary tissue 3 lymph nodes up to 1.5 cm metastatic nature, subclavian and the subscapularis kletchatkoj enlarged lymph nodes are not defined. Histogenesis No. 867088-98: in the breast after chemotherapy pronounced sclerosis, hyalinosis, single hyperchromic cells, like tumor, axillary tissue lymph nodes (2) - metastatic ductal cancer. In June 2006, postoperative remote gamma-therapy (DHT) on postoperative scar and area regional lymphatic drainage, SOD 36 Gy (40 sogr). July is adjuvant polychemotherapy. At the present time there were 4 courses of adjuvant chemotherapy on autoplasma. As a result of combined treatment, the patient is in III clinical group, feels good, no complaints. Has 3 children, housewife, performs without limitation the housework. In this way treated 23 patients. Partial regression of the tumor, according to the who criteria, was observed in 69,0% of cases, stabilization - 13.0% in the absence of progression of the tumor process. Morphologically complete regression of tumors observed in 27.3% of cases, 72.7% of the partial regression. Conducted 48 courses of neoadjuvant chemotherapy on protein concentrate autoplasma, 34 rate (70.8 per cent) migrated bol is generated without complications. Side effects observed in 29.2% of cases manifested gastrointestinal toxicity and hematologic - leukopenia II degree in 12.8% of cases. Which indicates the low toxicity of the way. Technical and economic efficiency of the Method neoadjuvant chemotherapy for breast cancer is that the conduct of chemotherapy on protein concentrate autoplasma, obtained by the method of filtration detoxification, improves the efficiency of treatment: patients are transferred from inoperable to operable condition, reducing the size of the tumor and lymph nodes, reducing the toxicity of chemotherapy, which reduces the additional costs of mild complications arising during treatment. The way neoadjuvant chemotherapy for breast cancer, including intravenous drip anticancer chemotherapeutic agents, characterized in that from the first day of treatment received vascular access autochrome in the amount of 2400-2600 ml centrifuged, 1600 ml of the supernatant plasma is taken in sterile vials, subjected to filtration detoxification using filter F60S with a perfusion rate of 250-300 ml/min, getting protein concentrate autoplasma volume 700-800 ml, placed in sterile vials equal portions corresponding to the number p is uniramia introductions drugs under the scheme, the vials contain in the refrigerator at t -20°With, for chemotherapy cytotoxic drugs schema protein concentrate is thawed at t+4°C, each cytostatic diluted in 10 ml saline solution, is injected into the vial containing protein concentrate, incubated at t+37,0°C for at least 30 minutes and is re-infused intravenous drip, hold 1-2 course of treatment.
|